Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy
Liuu et al.
The finding, in our words
The GOLD pathway using home capillary blood glucose monitoring proved feasible and safe in 126 older adults with cancer on steroid therapy, with diabetes medication intervention needed in 32% but only two diabetes-related hospitalisations and three asymptomatic hypoglycaemic events, suggesting effective hyperglycaemia management without excess risk.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This proof-of-concept study demonstrated that patients with inflammatory bowel disease could successfully perform capillary blood microsampling at home with high analytical success rates, and a majority preferred this decentralised approach over hospital venous draws.
Schuurman et al., Inflammatory bowel diseases · source ↗
In a Phase 1 crossover study of etrasimod, self-collected blood microsamples yielded pharmacokinetic exposures comparable to conventional venous sampling, both with and without participant practice sessions. Continuous wearable sensors concurrently enabled real-time remote monitoring of safety vital signs and electrocardiograms, demonstrating the viability of hybrid decentralised designs in early-phase clinical trials.
Malhotra et al., Clinical pharmacology and therapeutics · source ↗
In this decentralised n-of-1 crossover trial of dapagliflozin in 20 adults with type 2 diabetes, remote collection of urine and capillary blood samples achieved 99.4% and 98.4% delivery success respectively, demonstrating that remote monitoring can reliably track individual albuminuria responses to therapy.
In a decentralised phase 1 trial, healthy adults used a clinical trial app to self-collect blood microsamples and vital signs at home, with 65 to 70 per cent successfully providing blood samples and most preferring self-collection over staff collection.
Ye et al., Contemporary clinical trials communications · source ↗
The Drawbridge OneDraw device enabled home blood collection with high acceptability, as 76 per cent of participants preferred it to finger-prick or venous methods and reported significantly lower pain scores. In a remote study of 4023 participants, sample return rates stayed above 89 per cent across three timepoints over six months, and antibody results agreed well with venous blood in a validation subset of 120 participants.
Koulman et al., Journal of telemedicine and telecare · source ↗